



# Unlocking the Full Potential of the Immune System Against Cancer

[www.transgene.fr](http://www.transgene.fr)





# Transgene designs and develops cutting-edge immunotherapies to fight cancer.

Our approaches aim to specifically stimulate and educate the immune system to enable it to recognize and destroy cancer cells.

Our treatments have the potential to empower patients in their fight against their disease.

Discover Transgene in a nutshell





## Transgene develops three innovative approaches:

- individualized neoantigen cancer vaccines
- shared antigens cancer vaccines
- oncolytic viruses

Our two most advanced assets are in Phase II clinical trials. Transgene has several research programs at the preclinical stage.

Discover Transgene's PortFolio





# Individualized cancer vaccine derived from the *myvac*<sup>®</sup> platform

## TG4050

# 1 patient, 1 cancer, 1 vaccine

At the crossroads of the latest technological, genomic, and medical innovations, this innovative immunotherapy capitalizes on artificial intelligence to personalize each treatment to each patient and stimulate a strong immune response against the cancer.

Based on Phase I promising data, Transgene and its partner NEC move forward with an extension of the randomized trial consisting of a Phase II part in head and neck cancer.

Discover TG4050





# Shared antigens cancer vaccine

## TG4001

**TG4001** is a therapeutic vaccine designed to stimulate the immune system against the E6 and E7 antigens of the human papillomavirus (HPV16), that are found in anogenital cancers.

Based on promising Phase I data, Transgene is currently conducting a randomized Phase II trial to demonstrate the efficacy of TG4001 in combination with another immunotherapy (Avelumab).

Results are expected by the end of 2024.

Discover TG4001





# Oncolytic viruses

# TG6050 and BT-001

Derived from the Invir.IO® platform, our oncolytic viruses **TG6050** and **BT-001** infect, specifically multiply and induce tumor cell lysis (or oncolysis).

Anti-cancer weapons have been integrated within their genomes, enabling them to modulate the tumor microenvironment.

These different mechanisms lead to the destruction of tumor cells and the activation of the immune system, while preserving the patient's own healthy cells.

New clinical data are expected for these two candidates by the end of 2024.

Discover oncolytic viruses





*To develop innovative treatments against cancers  
for which there is no satisfactory treatment.*

*Our mission carries the values of corporate social  
responsibility in itself.*

*Transgene has always paid particular attention to  
ESG and has always promoted the values of humanism,  
citizenship, and respect for the environment*

Discover our ESG report in the URD 2023, chapter 4







72%  
of employees are  
dedicated to Research  
and Innovation

From discovery  
to individualized  
batch production

160  
employees

110  
Patents  
worldwide



Boulevard Gonthier d'Andernach  
Parc d'innovation CS80166  
67405 ILLKIRCH-GRAFFENSTADEN CEDEX - FRANCE

[www.transgene.fr](http://www.transgene.fr)

